Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy

• Published in: BMC cancer Vol. 22; no. 1; pp. 1249 - 15
• Main Authors: Jiang, Cong, Xiu, Yuting, Yu, Xiao, Qiao, Kun, Zhang, Shiyuan, Huang, Yuanxi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.12.2022; BioMed Central; BMC
• Subjects: Adjuvant treatment; Albumins; Biomarkers; Breast cancer; Cancer; Care and treatment; Chemotherapy; Development and progression; Evaluation; Health risk assessment; Humans; Inflammation; Inflammatory Breast Neoplasms - drug therapy; Interaction; Leukocytes (neutrophilic); Lymphocytes; Malnutrition; Medical prognosis; mSIS; Neoadjuvant Therapy; Nomogram; Nomograms; Patients; Prognosis; Retrospective Studies; Risk groups; Surgery; Tumors; China; mSIS; Breast cancer; Interaction; Nomogram

The modified systemic inflammation score (mSIS) system, which is constructed based on the neutrophil to lymphocyte ratio (NLR) and albumin (Alb), has not been applied to evaluate the prognosis of malignant breast cancer patients who underwent neoadjuvant chemotherapy (NAC). The present study aimed t...